Association of the (CA) n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency

Maria Consolata Miletta, Ursina A. Scheidegger, Mara Giordano, Mauro Bozzola, Sara Pagani, Gianni Bona, Mehul Dattani, Peter C. Hindmarsh, Vibor Petkovic, Monika Oser-Meier, Christa E. Flück, Primus E. Mullis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: A number of mathematical models for predicting growth and final height outcome have been proposed to enable the clinician to 'individualize' growth-promoting treatment. However, despite optimizing these models, many patients with isolated growth hormone deficiency (IGHD) do not reach their target height. The aim of this study was to analyse the impact of polymorphic genotypes [CA repeat promoter polymorphism of insulin-like growth factor-I (IGF-I) and the -202 A/C promoter polymorphism of IGF-Binding Protein-3 (IGFBP-3)] on variable growth factors as well as final height in severe IGHD following GH treatment. Design, Patients and Controls: One hundred seventy eight (IGF-I) and 167 (IGFBP-3) subjects with severe growth retardation because of IGHD were studied. In addition, the various genotypes were also studied in a healthy control group of 211 subjects. Results The frequency of the individual IGF-I (CA) n repeats ranging from 10 to 24, with the most frequent allele containing CA 19, was similar in controls and in IGHD subjects. However, in controls, the pooled CA 19 and CA 20 as well as -202 A IGFBP-3 alleles were significantly (P <0.01 and P <0.001) more common in the taller [≥2 to 0 standard deviation score (SDS)] when compared with the shorter subgroup (

Original languageEnglish
Pages (from-to)683-690
Number of pages8
JournalClinical Endocrinology
Volume76
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Pituitary Dwarfism
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Growth Hormone
Growth
Alleles
Genotype
Intercellular Signaling Peptides and Proteins
Theoretical Models
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Association of the (CA) n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency. / Miletta, Maria Consolata; Scheidegger, Ursina A.; Giordano, Mara; Bozzola, Mauro; Pagani, Sara; Bona, Gianni; Dattani, Mehul; Hindmarsh, Peter C.; Petkovic, Vibor; Oser-Meier, Monika; Flück, Christa E.; Mullis, Primus E.

In: Clinical Endocrinology, Vol. 76, No. 5, 05.2012, p. 683-690.

Research output: Contribution to journalArticle

Miletta, Maria Consolata ; Scheidegger, Ursina A. ; Giordano, Mara ; Bozzola, Mauro ; Pagani, Sara ; Bona, Gianni ; Dattani, Mehul ; Hindmarsh, Peter C. ; Petkovic, Vibor ; Oser-Meier, Monika ; Flück, Christa E. ; Mullis, Primus E. / Association of the (CA) n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency. In: Clinical Endocrinology. 2012 ; Vol. 76, No. 5. pp. 683-690.
@article{28dddc85340b41729d5bdaeaa09e7d4e,
title = "Association of the (CA) n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency",
abstract = "Objective: A number of mathematical models for predicting growth and final height outcome have been proposed to enable the clinician to 'individualize' growth-promoting treatment. However, despite optimizing these models, many patients with isolated growth hormone deficiency (IGHD) do not reach their target height. The aim of this study was to analyse the impact of polymorphic genotypes [CA repeat promoter polymorphism of insulin-like growth factor-I (IGF-I) and the -202 A/C promoter polymorphism of IGF-Binding Protein-3 (IGFBP-3)] on variable growth factors as well as final height in severe IGHD following GH treatment. Design, Patients and Controls: One hundred seventy eight (IGF-I) and 167 (IGFBP-3) subjects with severe growth retardation because of IGHD were studied. In addition, the various genotypes were also studied in a healthy control group of 211 subjects. Results The frequency of the individual IGF-I (CA) n repeats ranging from 10 to 24, with the most frequent allele containing CA 19, was similar in controls and in IGHD subjects. However, in controls, the pooled CA 19 and CA 20 as well as -202 A IGFBP-3 alleles were significantly (P <0.01 and P <0.001) more common in the taller [≥2 to 0 standard deviation score (SDS)] when compared with the shorter subgroup (",
author = "Miletta, {Maria Consolata} and Scheidegger, {Ursina A.} and Mara Giordano and Mauro Bozzola and Sara Pagani and Gianni Bona and Mehul Dattani and Hindmarsh, {Peter C.} and Vibor Petkovic and Monika Oser-Meier and Fl{\"u}ck, {Christa E.} and Mullis, {Primus E.}",
year = "2012",
month = "5",
doi = "10.1111/j.1365-2265.2011.04267.x",
language = "English",
volume = "76",
pages = "683--690",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Association of the (CA) n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency

AU - Miletta, Maria Consolata

AU - Scheidegger, Ursina A.

AU - Giordano, Mara

AU - Bozzola, Mauro

AU - Pagani, Sara

AU - Bona, Gianni

AU - Dattani, Mehul

AU - Hindmarsh, Peter C.

AU - Petkovic, Vibor

AU - Oser-Meier, Monika

AU - Flück, Christa E.

AU - Mullis, Primus E.

PY - 2012/5

Y1 - 2012/5

N2 - Objective: A number of mathematical models for predicting growth and final height outcome have been proposed to enable the clinician to 'individualize' growth-promoting treatment. However, despite optimizing these models, many patients with isolated growth hormone deficiency (IGHD) do not reach their target height. The aim of this study was to analyse the impact of polymorphic genotypes [CA repeat promoter polymorphism of insulin-like growth factor-I (IGF-I) and the -202 A/C promoter polymorphism of IGF-Binding Protein-3 (IGFBP-3)] on variable growth factors as well as final height in severe IGHD following GH treatment. Design, Patients and Controls: One hundred seventy eight (IGF-I) and 167 (IGFBP-3) subjects with severe growth retardation because of IGHD were studied. In addition, the various genotypes were also studied in a healthy control group of 211 subjects. Results The frequency of the individual IGF-I (CA) n repeats ranging from 10 to 24, with the most frequent allele containing CA 19, was similar in controls and in IGHD subjects. However, in controls, the pooled CA 19 and CA 20 as well as -202 A IGFBP-3 alleles were significantly (P <0.01 and P <0.001) more common in the taller [≥2 to 0 standard deviation score (SDS)] when compared with the shorter subgroup (

AB - Objective: A number of mathematical models for predicting growth and final height outcome have been proposed to enable the clinician to 'individualize' growth-promoting treatment. However, despite optimizing these models, many patients with isolated growth hormone deficiency (IGHD) do not reach their target height. The aim of this study was to analyse the impact of polymorphic genotypes [CA repeat promoter polymorphism of insulin-like growth factor-I (IGF-I) and the -202 A/C promoter polymorphism of IGF-Binding Protein-3 (IGFBP-3)] on variable growth factors as well as final height in severe IGHD following GH treatment. Design, Patients and Controls: One hundred seventy eight (IGF-I) and 167 (IGFBP-3) subjects with severe growth retardation because of IGHD were studied. In addition, the various genotypes were also studied in a healthy control group of 211 subjects. Results The frequency of the individual IGF-I (CA) n repeats ranging from 10 to 24, with the most frequent allele containing CA 19, was similar in controls and in IGHD subjects. However, in controls, the pooled CA 19 and CA 20 as well as -202 A IGFBP-3 alleles were significantly (P <0.01 and P <0.001) more common in the taller [≥2 to 0 standard deviation score (SDS)] when compared with the shorter subgroup (

UR - http://www.scopus.com/inward/record.url?scp=84859649797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859649797&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2011.04267.x

DO - 10.1111/j.1365-2265.2011.04267.x

M3 - Article

VL - 76

SP - 683

EP - 690

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 5

ER -